Quality & documentation
One Vial, Four Analytes: Reading a KLOW Certificate
Published: August 25, 2026
TL;DR
An 80 mg KLOW vial is specified as GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. Those four masses add to the 80 mg on the label, so every milligram is assigned to a named peptide. What that leaves is a documentation question rather than a composition one: four named analytes, four separate identity records, one certificate. Exact four-name searches return no combination-level PubMed record and no ClinicalTrials.gov study, so the published evidence belongs to the components rather than to the set. Three of the four now carry a July 2026 FDA committee recommendation. The largest by mass does not.
Curo lists this material as KLOW 80 mg in the research peptide catalogue. Lot documents are searchable through the COA library, and the guide to verifying a certificate against its lot covers the check itself.
One label mass, four named peptides
Start with the arithmetic, because it closes. GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. Eighty milligrams, which is exactly the mass the label carries. Nothing is left over and nothing is unassigned.
That matters more than it sounds. A blend described only as proportions leaves a reader converting ratios before they can check anything. A blend with a stated mass per component gives a certificate something specific to be measured against, one analyte at a time.
The four named entries still need care. KLOW is one vial and four analytes. It has no single sequence, no single formula and no single UNII, so its paperwork has to keep two levels apart. The lot answers which vial was tested. Analyte identity answers which named material produced a given signal. Assay answers how much of that analyte was there. Collapse those into one overall peptide figure and the composition detail a reader came for is gone.
That is why a useful KLOW certificate begins with correspondence: the lot on the vial should match the lot on the document, and the reported analytes should match the four names in the stated composition. Curo's quality and testing standard provides the broader context for reading those records. KLOW remains within Curo's research-use-only scope.
The four-name record stops at the components
KLOW's combination-level record is unusually easy to describe because the search terms are exact. A search for GHK-Cu, BPC-157, TB-500, and KPV together returns zero PubMed records. The matching four-name search returns zero ClinicalTrials.gov studies.
Evidence attached to a component belongs to that component. Formulation, relative mass, matrix and the presence of the other three all differ once the four are in one vial. Nothing in those searches studied KLOW as specified.
The closest located experiment is a rat Achilles-tendon study of BPC-157 and TB-500. It included separate BPC-157 and TB-500 groups as well as a group receiving the two together. That pair covers two of KLOW's four named components, uses different weights, and includes neither GHK-Cu nor KPV. It is the nearest combination on the record, but it is not a KLOW study.
Four names require four precise identities
The component names reveal why identity is the most useful part of a KLOW certificate. They do not all describe the same kind of molecular entry.
FDA files GHK-Cu under the preferred name PREZATIDE COPPER. The record gives formula C14H22N6O4.Cu and UNII 6BJQ43T1I9. Copper appears in the formula, so this identity is a copper complex rather than the bare tripeptide. Readers who want to examine the largest component by weight on its own can follow GHK-Cu as a cosmetic ingredient and research chemical, because its copper complex already raises the identity question that this blend multiplies.
BPC-157 carries UNII 8ED8NXK95P. That identifier belongs to the BPC-157 component, not to KLOW as a whole.
FDA describes TB-500 as the N-acetylated Leu-Lys-Lys-Thr-Glu-Thr-Gln fragment and assigns UNII QHK6Z47GTG. The TB-500 and thymosin beta-4 fragment distinction is worth following because the component name covers a fragment rather than the parent protein, exactly the kind of detail a blend certificate has to pin down.
KPV expands to Lys-Pro-Val. The FDA UNII service returned no exact result for KPV or LYS-PRO-VAL. That absence should not be filled with a borrowed identifier. On a multi-analyte document, one mistaken mapping can make a clean-looking identity table ambiguous.
What multi-analyte quality control would need to resolve
Two published quality-control papers show the analytical shape of this problem. Neither method is validated for KLOW. They demonstrate how other peptide mixtures have been separated, quantified, and assigned identities.
In the first, researchers used liquid chromatography with electrospray mass spectrometry to separate a goserelin synthesis mixture. Mass spectrometry then supported identity assignments for the target peptide and peptide side-products. The useful idea for reading KLOW paperwork is the division of labor: chromatographic separation resolves mixture components, while mass information supports the identity assigned to each separated signal.
The second paper describes one-run UHPLC quality control for a 32-peptide pool. The method quantified the peptides by UV and confirmed identity by high-resolution mass spectrometry. A pool much larger than KLOW can therefore be approached as multiple analytes within one run, rather than as one undifferentiated peptide value.
Neither publication supplies KLOW acceptance criteria or establishes a KLOW purity method. They show the shape of the question, not its answer. For a four-analyte vial, a reader would look for separation sufficient to distinguish the named components, identity support for each reported signal, and a quantity tied to each analyte. The copper-bearing identity of GHK-Cu adds another defined feature, but these papers do not establish a particular copper measurement for KLOW.
Three components recommended, the biggest one absent
The regulatory entry is a meeting notice with a specific list. Under docket FDA-2025-N-6895, the Federal Register notice for the July 23, 2026 session listed BPC-157, KPV and TB-500 substances, each as free base and acetate, alongside MOTS-c. The session concerned bulk drug substances nominated for the Section 503A Bulk Drug Substances List.
All three were recommended. Voting separately on each form, the committee backed BPC-157, KPV and TB-500 by 8 in favor to 6 against with one abstention, the same tally in every case. Hyman, Phelps & McNamara reported that split, and Pharmaceutical Executive and McDermott Will & Schulte published matching figures. A recommendation is advisory, so none of the three is on the 503A list today; that takes agency rulemaking.
GHK-Cu was not on the agenda at all, and KLOW is not named as a blend anywhere in the notice. So three of the four components now carry a committee recommendation, the largest component by mass carries none, and the blend itself carries no regulatory status of its own. Those are three separate positions on one label.
Common questions
How is the 80 mg split between the four peptides?
GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. The four add to the 80 mg on the label. A certificate that reports a quantity per named analyte can be checked against those masses directly.
Has KLOW been studied as a four-peptide blend?
No combination-level record was located for the specified set. The nearest study combined only BPC-157 and TB-500 at different weights and did not include GHK-Cu or KPV.
Can one overall purity number describe all four KLOW analytes?
One number cannot show which signal belongs to GHK-Cu, BPC-157, TB-500, or KPV. The useful certificate fields are analyte-specific separation, identity assignment, and quantity, with the vial lot linked to the document.
Was KLOW listed in the July 23, 2026 Federal Register notice?
No. The notice named BPC-157, KPV and TB-500 substances, each as free base and acetate, alongside MOTS-c. The committee recommended all three by 8 to 6 with one abstention. It did not name GHK-Cu, and it did not name KLOW.